A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/28/2019 |
| Start Date: | May 2006 |
| End Date: | June 2007 |
A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement
This study is to assess if DU176b is effective in prevention of blood clots following hip
replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up
visits.
replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up
visits.
1. 18 years of age or older; male or female.
2. Able to provide written informed consent.
3. Must be scheduled for elective unilateral total hip replacement surgery. Only primary
surgeries accepted.
4. If female, must be either one year post-menopausal, surgically sterile, or using
medically accepted contraceptive measures as judged by the Investigator and in
accordance with local regulatory requirements.
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials